DAYBUE helps, but ACP-204 still decides upside
- ACADIA has two approved drugs: NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome.
- In Q1 2026, NUPLAZID net sales were $166.9 million and DAYBUE net sales were $101.2 million.
- DAYBUE grew 20% year over year in Q1, helped by faster than expected uptake of the new STIX powder form.
- A June 2026 positive CHMP opinion improved the Europe story for Daybu, but the European Commission still has to give final legal approval.
- The biggest pipeline test is ACP-204 in Alzheimer's disease psychosis, with top-line Phase 2 results expected from August to October 2026.
- Finn's scores point to a decent business with good financial health, but not a cheap stock.
Two drugs, one big readout
ACADIA is no longer a pure research story. It sells two FDA-approved medicines and uses that cash to fund more CNS drug work. Q1 2026 showed why the setup is interesting: DAYBUE had $101.2 million of net sales and grew 20% year over year, helped by strong early demand for DAYBUE STIX.
NUPLAZID is the steadier part of the story. It had $166.9 million of Q1 2026 net sales. Growth was only 6% on an adjusted basis because some patients refilled later than usual in January and February, but management said that issue had normalized.
The Europe question for DAYBUE improved after the CHMP gave Daybu a positive opinion in June 2026. That lowered a major overhang, but final European Commission approval is still the next legal step. It also does not solve the bigger question of how much global demand can grow after the first waves of use.
The main swing factor is ACP-204, also called remlifanserin, in Alzheimer's disease psychosis. Top-line Phase 2 results are expected from August to October 2026. A strong result could open a large market. A weak result would leave ACADIA much more dependent on NUPLAZID and DAYBUE.
Sales fund the science
ACADIA makes money by selling prescription drugs. NUPLAZID treats hallucinations and delusions linked to Parkinson's disease psychosis. DAYBUE treats Rett syndrome, a rare brain and development disorder.
This model is healthier than many biotech models because the company is commercial stage, cash-flow positive, and has no debt in the internal view. That means its existing products can help pay for research instead of relying only on new stock sales or borrowing.
The weak point is concentration. All product revenue comes from two medicines. If DAYBUE use slows, NUPLAZID loses exclusivity earlier than hoped, or ACP-204 fails, the long-term growth story gets thinner fast.
Valuation also matters. The business is better funded than many biotech peers, but Finn's valuation score is modest, so investors are already paying for part of the good news.
What ACADIA sells and studies
NUPLAZID
NUPLAZID is approved in the U.S. for hallucinations and delusions tied to Parkinson's disease psychosis. It is the mature profit engine, but refill timing, rebates, exclusivity, and future Medicare pricing all matter.
DAYBUE
DAYBUE is the first FDA-approved treatment for Rett syndrome. Q1 2026 net sales were $101.2 million, and the new STIX powder form appears to be helping adoption.
Daybu in Europe
Daybu, the European name for trofinetide, received a positive CHMP opinion in June 2026 after an earlier negative process. Final European Commission approval is still needed before broad EU commercialization.
ACP-204
ACP-204 is a next-generation 5HT2A compound being tested in Alzheimer's disease psychosis. The August to October 2026 Phase 2 readout is the biggest near-term pipeline event.
ACP-711
ACP-711 is a potential first-in-class GABA-Alpha-3 positive allosteric modulator for essential tremor. A Phase 2 study is expected to begin in Q4 2026 or Q1 2027.
ACP-271
ACP-271 is a GPR88 agonist aimed at tardive dyskinesia and Huntington's disease. A Phase 1 study was planned for Q1 2026 in the internal pipeline view.
ACP-101
ACP-101 was once a Phase 3 candidate for Prader-Willi syndrome. Development was stopped in September 2025, so it is no longer a growth driver.
Revenue is all product sales
ACADIA reports as one operating segment, but Q1 2026 product sales were split between NUPLAZID and DAYBUE. The mix below uses Q1 2026 net product sales of $166.9 million for NUPLAZID and $101.2 million for DAYBUE.
What could break the thesis
ACP-204 misses in Alzheimer's disease psychosis
High impact · Medium oddsThe pipeline is now heavily tied to ACP-204 after ACP-101 was discontinued. A weak Phase 2 result would remove the largest near-term value creation chance and make the company look more like a two-product commercial biotech.
DAYBUE STIX uptake fades
High impact · Medium oddsQ1 2026 strength came partly from faster than expected STIX uptake. The key question is whether that continues and whether it brings back patients who stopped the liquid form. If persistency does not improve, early demand could prove front-loaded.
Europe approval still stalls
Medium impact · Low oddsThe June 2026 positive CHMP opinion lowered the risk for Daybu in Europe. Still, the European Commission must issue final legal approval before the product can move into a real EU launch. Pricing and reimbursement by country can also slow revenue even after approval.
NUPLAZID growth re-slows
Medium impact · Medium oddsNUPLAZID is a mature franchise. Q1 2026 had a patient refill lag that management called temporary, but it showed how quarterly sales can wobble. Higher rebates also hurt historical net revenue in 2025.
Exclusivity and pricing pressure
Medium impact · Medium oddsACADIA believes it met requirements for a six-month pediatric exclusivity extension for NUPLAZID, but FDA approval is not guaranteed. NUPLAZID could also face Medicare price negotiation as early as 2029, though the company expects possible small manufacturer exemptions to limit early impact.
In one breath
What does ACADIA Pharmaceuticals do?
ACADIA develops and sells drugs for central nervous system disorders. Its main products are NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome.
Why does DAYBUE STIX matter?
DAYBUE STIX is a powder form of DAYBUE. Management said early uptake was faster than expected, which could help new patients start treatment and some former patients restart.
What is the biggest ACADIA catalyst in 2026?
The biggest clinical catalyst is the ACP-204 Phase 2 readout in Alzheimer's disease psychosis, expected from August to October 2026. A positive result could change the long-term growth outlook.
Is ACADIA profitable?
The internal company view describes ACADIA as cash-flow positive with no debt. That gives it more flexibility than many biotechs, but the business still depends on two products and clinical trial success.